Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-52.40% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
LGL · Jun 30, 2026
LGL GROUP INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001437749-26-028064General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
52.75% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
83.73% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-59.60% · CORE · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
21.33% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History8 statesHistory building
Period transition
What moved in the state?
- Previous
- 73.46%
- Current
- -52.40%
- Delta
- -125.86%
- Previous
- 36.95%
- Current
- 52.75%
- Delta
- 15.80%
- Previous
- 40.76%
- Current
- 83.73%
- Delta
- 42.97%
- Previous
- -115.10%
- Current
- -59.60%
- Delta
- 55.50%
- Previous
- 100.88%
- Current
- 21.33%
- Delta
- -79.55%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Electronic Components, Nec peers →Transitioned To · LGL Fundamental State →Transitioned To · LGL CASH_GENERATION_DECREASED →Transitioned To · LGL GROWTH_INCREASED →Transitioned To · LGL INVENTORY_PRESSURE_INCREASED →Transitioned To · LGL PROFITABILITY_INCREASED →Transitioned To · LGL SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.